Zilver® Flex™ Vascular Stent Study
Primary Purpose
Peripheral Arterial Disease (PAD)
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Zilver® Flex™ Vascular Stent
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Arterial Disease (PAD) focused on measuring Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria:
- Patients who are at least 18 years old and have at least 1 stenotic atherosclerotic lesion of the above-the-knee femoropopliteal artery may be considered for enrollment.
- To be enrolled in the study, the lesion must be the appropriate size and and no prior stent in the target vessel may be present.
Exclusion Criteria:
- Patient is < 18 years of age.
- Patient is pregnant or breast-feeding.
- Patient is simultaneously participating in an investigational drug or device study. The patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrollment in this study.
- Patient has had previous stenting of the target vessel.
- Patient has a medical condition or disorder that would limit life expectancy to less than 1 year or that may cause noncompliance with the protocol or confound the data analysis.
- Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated.
- Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- Patient has known hypersensitivity or contraindication to aspirin, antiplatelet medication, contrast dye, or nitinol that, in the opinion of the investigator, cannot be adequately premedicated.
Sites / Locations
- Herz-Zentrum
- Gemeinschaftspraxis
- Universitatsklinikum Magdeburg
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
1
Arm Description
single arm non-randomized post-market study
Outcomes
Primary Outcome Measures
Primary patency of the treated lesion within the superficial femoral artery
Secondary Outcome Measures
Procedural success and primary-assisted and secondary patency, thrombosis/total occlusion rate, clinical improvement, and functional status improvement
Full Information
NCT ID
NCT00827619
First Posted
January 22, 2009
Last Updated
December 3, 2015
Sponsor
Cook Group Incorporated
1. Study Identification
Unique Protocol Identification Number
NCT00827619
Brief Title
Zilver® Flex™ Vascular Stent Study
Official Title
Evaluation of the Zilver® Flex™ Vascular Stent in the Above-the-Knee Femoropopliteal Artery
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
November 2011 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cook Group Incorporated
4. Oversight
5. Study Description
Brief Summary
This study is intended to evaluate the long-term effectiveness of treatment of de novo or restenotic lesions of the above-the-knee femoropopliteal artery using the Zilver® Flex™ Vascular Stent which has received the CE mark for commercial use. The study is designed as a single arm non-randomized post-approval study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease (PAD)
Keywords
Peripheral Arterial Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
110 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Other
Arm Description
single arm non-randomized post-market study
Intervention Type
Device
Intervention Name(s)
Zilver® Flex™ Vascular Stent
Other Intervention Name(s)
Stenting, Vascular Stent, Implant
Intervention Description
Stenting of the Above-the-Knee Femoropopliteal Artery
Primary Outcome Measure Information:
Title
Primary patency of the treated lesion within the superficial femoral artery
Time Frame
1 year after patient enrollment
Secondary Outcome Measure Information:
Title
Procedural success and primary-assisted and secondary patency, thrombosis/total occlusion rate, clinical improvement, and functional status improvement
Time Frame
1 year after patient enrollment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who are at least 18 years old and have at least 1 stenotic atherosclerotic lesion of the above-the-knee femoropopliteal artery may be considered for enrollment.
To be enrolled in the study, the lesion must be the appropriate size and and no prior stent in the target vessel may be present.
Exclusion Criteria:
Patient is < 18 years of age.
Patient is pregnant or breast-feeding.
Patient is simultaneously participating in an investigational drug or device study. The patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrollment in this study.
Patient has had previous stenting of the target vessel.
Patient has a medical condition or disorder that would limit life expectancy to less than 1 year or that may cause noncompliance with the protocol or confound the data analysis.
Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated.
Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
Patient has known hypersensitivity or contraindication to aspirin, antiplatelet medication, contrast dye, or nitinol that, in the opinion of the investigator, cannot be adequately premedicated.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jens Ricke, MD
Organizational Affiliation
Universitatsklinikum Magdeburg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Herz-Zentrum
City
Bad Krozingen
ZIP/Postal Code
79189
Country
Germany
Facility Name
Gemeinschaftspraxis
City
Leipzig
ZIP/Postal Code
04177
Country
Germany
Facility Name
Universitatsklinikum Magdeburg
City
Magdeburg
ZIP/Postal Code
39120
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Zilver® Flex™ Vascular Stent Study
We'll reach out to this number within 24 hrs